LivaNova Director Sells 1,650 Shares for $131,500
The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
The Motley Fool9/11/2026Neutral
LIVN
LivaNova PLCNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$4.21B
P/E Ratio
22.60
EPS
$3.39
Beta
0.87
52W High
$85.76
52W Low
$48.82
50-Day MA
$79.65
200-Day MA
$70.96
Dividend Yield
—
Profit Margin
12.80%
Forward P/E
16.00
PEG Ratio
0.93
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.47B |
| Gross Profit (TTM) | $996.85M |
| EBITDA | $260.14M |
| Operating Margin | 13.50% |
| Return on Equity | 15.40% |
| Return on Assets | 5.04% |
| Revenue/Share (TTM) | $26.89 |
| Book Value | $24.07 |
| Price-to-Book | 3.23 |
| Price-to-Sales (TTM) | 2.87 |
| EV/Revenue | 2.8 |
| EV/EBITDA | 20.03 |
| Quarterly Earnings Growth (YoY) | 287.80% |
| Quarterly Revenue Growth (YoY) | 10.80% |
| Shares Outstanding | $54.93M |
| Float | $54.84M |
| % Insiders | 0.41% |
| % Institutions | 113.07% |
Historical Volatility
HV 10-Day
26.08%
HV 20-Day
23.90%
HV 30-Day
23.42%
HV 60-Day
32.66%
HV Rank
2.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($89.10 target)
2
Strong Buy6
Buy2
HoldLatest News
Artisan International Small-Mid Fund Q2 2026 Portfolio Review
Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.
Seeking Alpha8/24/2026Neutral
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
Zacks Investment Research8/6/2026Positive
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
LivaNova Q2 Earnings Call Highlights
LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.
MarketBeat8/5/2026Neutral
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research8/5/2026Neutral
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research8/5/2026Positive
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.
Zacks Investment Research8/5/2026Positive
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
Zacks Investment Research7/17/2026Negative
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research7/7/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LIVN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026